An 2017.

Methods	Study design: randomised clinical trial Study duration: January 2013 to January 2015 Duration of follow‐up: 2 years Setting: hospital
Participants	Number of participants: 98 Inclusion criteria: diagnosed as HCC; single or huge tumour; no PVTT; no history of other tumours Age (mean ± SD, range): TACE + MWA: 51.3 ± 2.9 years, 24‐78 years; TACE alone: 50.3 ± 2.6 years, 23‐78 years Male (n/total): TACE + MWA: 40/49; TACE alone: 39/49
Interventions	TACE + MWA group (n = 49): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: adriamycin 40 mg and fluorouracil 1 g MWA: the interval between TACE and MWA was 2 weeks. Output power of 50‐60W. Time of 10‐20 minutes per ablation application Control group (n = 49): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: adriamycin 40 mg and fluorouracil 1 g
Outcomes	Tumour response: measured by contrast‐enhanced CT; at 4 months after treatment 1‐year and 2‐year survival rates: measured at 1 year and 2 years after treatment Adverse events
Notes	Country of study: China Source of funding: none There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.